In which Her2+ breast cancer patients would you recommend extended adjuvant therapy with neratinib?  

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.



Answer from: Medical Oncologist at Academic Institution